These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 7600910)

  • 21. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin.
    Jolling K; Perez Ruixo JJ; Hemeryck A; Vermeulen A; Greway T
    Eur J Pharm Sci; 2005 Apr; 24(5):465-75. PubMed ID: 15784336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic/pharmacodynamic (PK/PD) evaluation of a once-daily treatment using ciprofloxacin in an extended-release dosage form.
    Schuck EL; Dalhoff A; Stass H; Derendorf H
    Infection; 2005 Dec; 33 Suppl 2():22-8. PubMed ID: 16518708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The release behavior of the combined system of diltiazem hydrochloride delayed-onset sustained-release pellets and modeling by mathematics method].
    Chen SJ; Zhu JB
    Yao Xue Xue Bao; 2005 Jul; 40(7):606-10. PubMed ID: 16196265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of a sustained-release dosage form of clomipramine.
    Herrera D; Mayet L; Galindo MC; Jung H
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1488-93. PubMed ID: 11185671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Study on dissolution test in vitro and bioavailability of oral osmotic pump of verapamil hydrochloride].
    Guo JL; Jing GW; Cao DS; Li YQ; He HY; Ling LX; Li Z
    Yao Xue Xue Bao; 1993; 28(9):714-20. PubMed ID: 8010021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Absorption profile and absolute bioavailability of a theophylline sustained-release preparation].
    Pabst G; Weber W; Barkworth MF; Müller M; Rehm KD
    Arzneimittelforschung; 1998 May; 48(5A):574-9. PubMed ID: 9676347
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct, differential-equation-based in-vitro-in-vivo correlation (IVIVC) method.
    Buchwald P
    J Pharm Pharmacol; 2003 Apr; 55(4):495-504. PubMed ID: 12803771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of tramadol and bioavailability of enteral tramadol formulations. 3rd Communication: suppositories.
    Lintz W; Barth H; Osterloh G; Schmidt-Böthelt E
    Arzneimittelforschung; 1998 Sep; 48(9):889-99. PubMed ID: 9793614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bioavailability and pharmacokinetic properties of 2 sustained-release formulations of diclofenac sodium, Voltaren vs inflaban: effect of food on inflaban bioavailability.
    Zmeili S; Hasan M; Najib N; Sallam E; Deleq S; Shubair M
    Int J Clin Pharmacol Ther; 1996 Dec; 34(12):564-70. PubMed ID: 8996854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PK/PD modelling of high-dose diltiazem--absorption-rate dependency of the hysteresis loop.
    Luckow V; Della Paschoa O
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):418-25. PubMed ID: 9352390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of gastroretentive microspheres and sustained-release preparations using theophylline pharmacokinetics.
    Miyazaki Y; Yakou S; Takayama K
    J Pharm Pharmacol; 2008 Jun; 60(6):693-8. PubMed ID: 18498704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative multiple dose pharmacokinetics of quinine, quinidine and quinidine sustained release.
    Jamaludin A; Mohamad M; Navaratnam V; Mohamed N; Yeoh PY; Wernsdorfer WH
    Acta Leiden; 1989; 58(2):129-40. PubMed ID: 2489392
    [No Abstract]   [Full Text] [Related]  

  • 33. [A simple method for predicting equality of absorption and elimination rate constants].
    Li JW; Zhang CL
    Zhongguo Yao Li Xue Bao; 1990 Sep; 11(5):392-4. PubMed ID: 2130592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Linear relationships in systems with non linear kinetics.
    Fagiolino P; Savio E; Stareczek S
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():485-96. PubMed ID: 1820928
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative bioavailability study of three sustained release quinidine formulations.
    Mahon WA; Leeder JS; Brill-Edwards MM; Correia J; MacLeod SM
    Clin Pharmacokinet; 1987 Aug; 13(2):118-24. PubMed ID: 3621768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absolute bioavailability of quinidine in two sustained release preparations.
    Amlie JP; Storstein L; Olsson B; Fremstad D; Jacobsen S
    Eur J Clin Pharmacol; 1979 Aug; 16(1):45-8. PubMed ID: 499299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo evaluation of controlled-release products.
    Hwang SS; Bayne W; Theeuwes F
    J Pharm Sci; 1993 Nov; 82(11):1145-50. PubMed ID: 8289130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Single-dose comparative kinetics and bioavailability study of quinine hydrochloride, quinidine sulfate and quinidine bisulfate sustained-release in healthy male volunteers.
    Jamaludin A; Mohamed M; Navaratnam V; Mohamed N; Yeoh E; Wernsdorfer W
    Acta Leiden; 1988; 57(1):39-46. PubMed ID: 3245401
    [No Abstract]   [Full Text] [Related]  

  • 39. Influence of food on the comparative bioavailability of a fast- and slow-release dosage form of quinidine gluconate.
    Spénard J; Sirois G; Gagnon MA
    Int J Clin Pharmacol Ther Toxicol; 1983 Jan; 21(1):1-9. PubMed ID: 6832862
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetics of oral extended-release dosage forms. I. Release kinetics, concentration, and absorbed fraction.
    Liu FY; Sambol NC; Giannini RP; Liu CY
    Pharm Res; 1995 May; 12(5):720-8. PubMed ID: 7479559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.